<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01657942</url>
  </required_header>
  <id_info>
    <org_study_id>PCa003</org_study_id>
    <nct_id>NCT01657942</nct_id>
  </id_info>
  <brief_title>Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions</brief_title>
  <official_title>Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that focal treatment with ExAblate MRgFUS has the potential&#xD;
      to be an effective non-invasive treatment for intermediate risk, organ-confined prostate&#xD;
      lesions, with a low incidence of morbidity. The study hypothesis will be tested by measuring&#xD;
      treatment-related safety and initial effectiveness parameters in the ExAblate MRgFUS treated&#xD;
      patients, as described above.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective of this pivotal trial is to assess safety and initial effectiveness of ExAblate&#xD;
      MRgFUS in the treatment of intermediate risk, localized (organ confined) prostate lesions.&#xD;
&#xD;
      ExAblate treatment will be implemented as a focal lesion-selective therapy, directed at&#xD;
      pre-defined volume(s)/sector(s) in the prostate, identified by mapping biopsy and&#xD;
      multi-parametric MRI, rather than a whole gland or hemi-ablation treatment.&#xD;
&#xD;
      Safety: evaluate incidence and severity of adverse events associated with ExAblate's MRgFUS&#xD;
      focal treatment of intermediate risk organ confined prostate lesions. The risk of ExAblate&#xD;
      treatment-related incontinence and impotence will also be assessed in this study.&#xD;
&#xD;
      Effectiveness: determine the lesion control effect of ExAblate's MRgFUS focal treatment of&#xD;
      intermediate risk organ-confined prostate lesions (confirmed by IMAGE-guided mapping biopsy&#xD;
      results).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of ExAblate MRgFUS focal treatment of intermediate risk organ confined prostate lesions</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate incidence and severity of adverse events associated with ExAblate's MRgFUS focal treatment of intermediate risk organ confined prostate lesions. The risk of ExAblate treatment-related incontinence and impotence will also be assessed in this study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness of ExAblate MRgFUS focal treatment of intermediate risk organ-confined prostate lesions</measure>
    <time_frame>6 months</time_frame>
    <description>Determine the lesion control effect of ExAblate's MRgFUS focal treatment of intermediate risk organ-confined prostate lesions (confirmed by IMAGE-guided mapping biopsy results).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Localized Intermediate Risk Prostate Lesions</condition>
  <arm_group>
    <arm_group_label>ExABlate MR Guided Focus Ultrasound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ExAblate MR Guided Focused Ultrasound</intervention_name>
    <description>ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.</description>
    <arm_group_label>ExABlate MR Guided Focus Ultrasound</arm_group_label>
    <other_name>ExAblate 2100 Prostate System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Biopsy proven adenocarcinoma of the prostate (using a IMAGE-guided 14+ core mapping&#xD;
             biopsy), and targeted cores as needed obtained up to 6 months prior to scheduled&#xD;
             treatment&#xD;
&#xD;
          -  Patient with intermediate risk, early-stage organ-confined prostate cancer (T1a up to&#xD;
             T2b, N0, M0) and voluntarily chooses ExAblate thermal ablation as the non-invasive&#xD;
             treatment, who may currently be on watchful waiting or active surveillance and not in&#xD;
             need of imminent radical therapy.&#xD;
&#xD;
          -  Patient with PSA less than or equal to 20 ng/mL&#xD;
&#xD;
          -  Gleason score 7 (4 + 3 or 3 + 4), based on mapping prostate biopsy, with no more than&#xD;
             15mm cancer in maximal linear dimension in any single core&#xD;
&#xD;
          -  Single hemilateral index Gleason 7 lesion, identified in the prostate based on biopsy&#xD;
             mapping with supporting MRI; may have secondary Gleason 6 lesion on ipsilateral or&#xD;
             contralateral side confirmed with biopsy and/or MRI&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Contraindications to MRI&#xD;
&#xD;
          -  History of orchiectomy, PCa-specific chemotherapy, brachytherapy, cryotherapy,&#xD;
             Photodynamic therapy or radical prostatectomy for treatment of prostate cancer; any&#xD;
             prior radiation therapy to the pelvis for prostate cancer or any other malignancy&#xD;
&#xD;
          -  Patient under medications that can affect PSA for the last 3 months prior to MRgFUS&#xD;
             treatment (Androgen Deprivation Treatment; alpha reductase inhibitors)&#xD;
&#xD;
          -  Individuals who are not able or willing to tolerate the required prolonged stationary&#xD;
             supine position during treatment (approximately 3 hrs. sonication time)&#xD;
&#xD;
          -  Any rectal pathology, anomaly or previous treatment, which could change acoustic&#xD;
             properties of rectal wall or prevent safe probe insertion (e.g., stenosis, fibrosis,&#xD;
             inflammatory bowel disease, etc.)&#xD;
&#xD;
          -  Evidence of distant prostate cancer, i.e., including lymph nodes and/or metastasis of&#xD;
             cancer on imaging&#xD;
&#xD;
          -  Bladder cancer&#xD;
&#xD;
          -  Urethral stricture/bladder neck contracture&#xD;
&#xD;
          -  Prostatitis NIH categories I, II and III&#xD;
&#xD;
          -  Implant near (&lt;1 cm) the prostate&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Behfar Ehdaie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sperling Prostate Center</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 2, 2012</study_first_submitted>
  <study_first_submitted_qc>August 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2012</study_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRgFUS</keyword>
  <keyword>Prostate</keyword>
  <keyword>Intermediate Risk Prostate Lesions</keyword>
  <keyword>Focal Prostate treatment</keyword>
  <keyword>InSightec</keyword>
  <keyword>ExAblate</keyword>
  <keyword>Non-invasive</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Gleason 7</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

